Free Alerts   Login
Health Care › Pharmaceutical Preparations

ARCT Stock Price Correlated With Arcturus Therapeutics Holdings Financials

ARCT Stock Price vs. Quarterly
ARCT
Income Statement
Cash Flow
Balance Sheet

ARCT Income Statement

Enable JavaScript and reload
Revenue, Net:
Revenue Per Share:
Cost of Goods & Services Sold:
Gross Profit:
Selling, General & Admin Expense:
Research & Development Expense:
Total Operating Expenses:
Operating Income:
Income Taxes:
Net Income:
Earnings Per Share, Diluted:
Earnings Per Share, Basic:
Shares Outstanding, Basic Avg:
Shares Outstanding, Diluted Avg:
Common Stock Shares Outstanding:

ARCT Cash Flow

Enable JavaScript and reload
Operating Activities Net Income:
Depreciation, Depletion & Amortization:
Change in Accounts Receiveable:
Net Cash from Operations:
Net Cash from Operations Per Share:
Repurchases/Buybacks Common Stock:
Issuance of Long-term Debt:
Cash Dividends Paid:
Net Cash from Financing Activities:
Property, Plant & Equipment Purchases:
Purchases of Businesses, Net of Cash:
Net Cash from Investing Activities:
Net Change in Cash & Equivalents:

ARCT Balance Sheet

Enable JavaScript and reload
Cash and Cash Equivalents:
Short-Term Investments:
Accounts Receivable, Net:
Inventories:
Total Current Assets:
Property, Plant & Equipment, Net:
Total Assets:
Accounts Payable:
Current Portion of Long-Term Debt:
Total Short-Term Liabilities:
Long Term Debt, Non-Current Portion:
Total Long-Term Liabilities:
Total Liabilities:

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Federated Hermes.
4,711,512 sh
 
$148,554
Blackrock.
2,398,296 sh
260,596 sh
12%
$75,620
$21,003
Ark Investment Management
2,047,687 sh
146,141 sh
8%
$64,564
$15,979
State Street
1,629,666 sh
-38,259 sh
-2%
$51,383
$8,768
Vanguard Group
1,458,380 sh
51,537 sh
4%
$45,983
$10,038
Nikko Asset Management Americas.
1,320,652 sh
-67,922 sh
-5%
$41,587
$6,164
Sumitomo Mitsui Trust Holdings.
1,320,652 sh
-67,922 sh
-5%
$41,640
$6,162
Dimensional Fund Advisors
1,088,930 sh
115,087 sh
12%
$34,336
$9,454
Woodline Partners Lp
1,069,814 sh
 
$33,731
FMR
864,358 sh
-75,923 sh
-8%
$27,253
$3,229
Morgan Stanley
581,997 sh
8,365 sh
1%
$18,350
$3,694
Geode Capital Management
538,265 sh
26,097 sh
5%
$16,973
$3,885
Granahan Investment Management/Ma
450,366 sh
51,504 sh
13%
$14,200
$4,009
Goldman Sachs Group
414,641 sh
69,156 sh
20%
$13,074
$4,247
Schonfeld Strategic Advisors
401,481 sh
401,481 sh
NEW
$12,659
$12,659
Jupiter Asset Management
362,344 sh
167,563 sh
86%
$11,425
$6,448
JPMorgan Chase
322,819 sh
-4,830 sh
-1%
$10,179
$1,808
Northernrp
246,999 sh
18,235 sh
8%
$7,788
$1,943
Great Lakes Advisors
207,127 sh
207,127 sh
NEW
$6,531
$6,531
Nuveen Asset Management
194,682 sh
336 sh
0%
$6,139
$1,173
COMPANY PROFILE
Note 1. Description of Business, Basis of Presentation and Summary of Significant Accounting Policies Description of Business Arcturus Therapeutics Holdings Inc. (the “Company” or "Arcturus") is a late-stage global clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. The Company became a clinical stage company during 2020 when it announced that its Investigational New Drug (“IND”) application for ornithine transcarbamylase (“OTC”) deficiency and its Clinical Trial Application (“CTA”) candidate LUNAR-COV19 were approved by applicable health authorities. Basis of Presentation The accompanying condensed consolidated financial statements include the accounts of Arcturus Therapeutics Holdings Inc. and its subsidiaries and are unaudited. All intercompany accounts and transactions have been eliminated in consolidation. These condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management’s opinion, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results for the interim periods presented. Interim financial results are not necessarily indicative of results anticipated for the full year. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and footnotes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. These condensed consolidated financial statements are prepared in accordance with GAAP, which requires management to make estimates and assumptions regarding the valuation of debt instruments, the equity-method investment, share-based compensation expense, accruals for liabilities, income taxes, revenue and deferred revenue, leases, and other matters that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although these estimates are based on management’s knowledge of current events and actions the Company may undertake in the future, actual results may ultimately differ from these estimates and assumptions.

Joint Ventures, Equity Method Investments and Variable Interest Entities Investments for which the Company exercises significant influence, but does not have control are accounted for under the equity method. Equity method investment activity is related to a 49 % joint venture with Axcelead, Inc. (see the following paragraph for further details) and a 12 % ownership in Vallon Pharmaceuticals, Inc. (see “ Note 10, Related Party Transactions ” for further details). The Company’s share of the investees’ results is presented as either income or loss from equity method investees in the accompanying condensed consolidated statements of operations and comprehensive loss. In April 2021, Arcturus and Axcelead, Inc., a company existing under the laws of Japan (“Axcelead”), formed a joint venture entity, named Arcalis, Inc. (“JV Entity”), which operates as a corporation under the laws of Japan. Axcelead is an integrated drug discovery solutions provider to the pharmaceutical industry in Japan. On July 1, 2017, Axcelead became the successor to a portion of the drug discovery research department of Takeda Pharmaceutical Company Limited. The goal of the JV Entity is to be a contract development and manufacturing organization focused on mRNA manufacturing that would provide manufacturing services to the Company and also to third parties. The joint venture includes a shareholders agree

Free historical financial statements for Arcturus Therapeutics Holdings Ltd. See how revenue, income, cash flow, and balance sheet financials have changed over 16 quarters since 2020. Compare with ARCT stock chart to see long term trends.

Data imported from Arcturus Therapeutics Holdings Ltd SEC filings. Check original filings before making any investment decision.